YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (HK:1558) has released an update.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. reported a 23.5% decrease in revenue and a 33.5% decline in profit for the first half of 2024 compared to the same period in 2023, despite increased R&D expenses and strong growth in its chronic disease business. The company did not declare an interim dividend and highlighted significant growth in its insulin products and oral hypoglycemic drugs, with the expectation that its new diabetes treatment, Rongliflozin, will significantly contribute to future performance.
For further insights into HK:1558 stock, check out TipRanks’ Stock Analysis page.